BioSpace News Archive

Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses.

Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced that the company will release financial results for the second quarter 2022 after the market close on Wednesday, August 10, 2022.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the second quarter ended June 30, 2022.

Amgen announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately.

BioMarin Pharmaceutical Inc. announced financial results for the second quarter ended June 30, 2022.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance and provided business updates.

Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2022, provided guidance for the third quarter of 2022 and updated its full-year 2022 guidance.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the second quarter and first half year of 2022.

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter ended June 30, 2022 and increased its 2022 revenue guidance.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported financial results for the second quarter ended June 30, 2022 and provided a review of recent business and clinical highlights.